What are gene therapies? What are some recent advancement in gene therapy? How does development in gene therapy differ from common drugs?

Today's episode is slightly different from the previous ones. It is the first time that TWO brilliant biostatisticians share their insight in the same episode! Avery McIntosh and Alex Sverdlov will answer all the questions about gene therapy for you!

Dr. McIntosh is currently engaged in drug development for rare diseases at Pfizer, where he leads a team of statisticians working across different study phases and a range of drug types and disease areas. Meanwhile, Dr. Sverdlov serves as the Neuroscience Disease Area statistical lead at Novartis, where he focuses on methodological research and the application of innovative statistical methods in drug development.

Other than an interesting gene therapy 101 that Avery and Alex gave in this episode, they also recently co-published a book called "Development of gene therapies: strategic, scientific, regulatory, and Access considerations", which is now available. I will put the link of the book in the show notes and please check it out if you are either a long term enthusiast of gene therapy or if you start to think gene therapy is interesting after listening to this episode. Let dive into this episode and see what Avery and Alex have shared with us.

You can find Avery and Alex's new book here.

Please visit our website https://biostatisticspodcast.github.io/ for the latest updates and transcripts of the published episodes.
If you have any comments, feedback, or suggestions, feel free to email us via biostatisticspodcast@gmail.com or DM us on Twitter @BiostatsPodcast

What is it like to work as a statistical methodologist in the industry? What is the importance of being collaborative and building leadership skills in the industry? How does "over-preparing" get you far in your career?

Godwin Yung will answer all these questions for you. Dr. Yung obtained his PhD in Biostatistics at Harvard University and currently works as a principal statistical methodologist at Genentech. He works on enabling the use of the most appropriate quantitative methodology in pharmaceutical development, including adaptive designs, estimands framework, borrowing external information, and surrogate endpoints etc. He also collaborates with external stakeholders outside of Genentech to advance the field of statistics. Let's dive into this episode and see what Godwin has shared with us.

You can find the FDA Overall Survival workshop here.

Please visit our website https://biostatisticspodcast.github.io/ for the latest updates and transcripts of the published episodes.
If you have any comments, feedback, or suggestions, feel free to email us via biostatisticspodcast@gmail.com or DM us on Twitter @BiostatsPodcast

What is it like to work as a statistician in the UCLA department of medicine statistics core? How do biostatisticians contribute to public policy making? What are some typical methods that are used in longitudinal studies?

Nicholas Jackson will answer all these questions for you. Dr. Jackson earned his PhD in Quantitative Psychology from University of Southern California, and now serves as an associated professor in the Division of general internal medicine and health services research in UCLA. His research interests span a broad spectrum, from sophisticated longitudinal methods to the cutting-edge machine learning methods of big data analysis. His practical work focuses on child and adolescent behavioural development, diabetes prevention. and health service research. Let's dive into this episode and see what Nick has shared with us.

Please visit our website https://biostatisticspodcast.github.io/ for the latest updates and transcripts of the published episodes.
If you have any comments, feedback, or suggestions, feel free to email us via biostatisticspodcast@gmail.com or DM us on Twitter @BiostatsPodcast